论文部分内容阅读
泽马可(tegaserod)是一种选择性5-HT_4受体部激动剂,能 有效缓解炎症性肠病(IBS)患者的腹痛、腹胀以及便秘症状。泽马可治疗可能会引起用药后一过性腹泻,其发生的机制可能与其药理学作用有关。此研究旨在观察泽马可对IBS患者及腹泻患者的作用,以对其安全性作进一步的评价。 方法:在经过两周的基线期观察后,将69例患者以双盲的方式分为3组(2:2:1),每天4mg泽马可治疗组(35例);每天12mg泽马可治疗组(34例)以及安慰剂治疗组(17例),共服药8周。入选患者必须在≥25％的时间内,至少满足2条罗马Ⅱ的腹泻标准。对观察期间患者的不良反应也同时进行了观察。
Tegaserod, a selective 5-HT4 receptor agonist, is effective in relieving abdominal pain, bloating and constipation in patients with inflammatory bowel disease (IBS). Zemake treatment may cause transient diarrhea after treatment, its mechanism may be related to its pharmacological effects. The aim of this study was to investigate the effect of zekomax on patients with IBS and diarrhea to further assess its safety. METHODS: After two weeks of baseline observation, 69 patients were divided into 3 groups (2: 2: 1) in a double-blind fashion, 4 mg zekuco treated group (n = 35) The treatment group (34 cases) and the placebo treatment group (17 cases) took a total of 8 weeks. Patients must be selected for ≥25% of the time, to meet at least two Rome II diarrhea standards. Adverse reactions to the patients during the observation period were also observed.